论文部分内容阅读
视网膜静脉阻塞多由血栓性阻塞所致。因此,广泛应用纤维素溶解酶以溶解血栓进行治疗,特别是对尿激酶的使用及剂量也有不少看法。而作者则主张大剂量给药。本文报告视网膜静脉阻塞时大量静脉点滴尿激酶,同时口服链激酶,伐里德酶(varidase)获得良好效果。作者于5个月内对门诊病人诊断为视网膜静脉阻塞者10例10眼进行治疗。尿激酶静脉点滴;同时伐里德酶1日3次,每次2丸,饭后服用。纤维溶解疗法的药物有尿激酶和链激酶,作用机制各不相同。链激酶作用于纤维蛋白溶酶原
Retinal vein occlusion and more caused by thrombotic obstruction. Therefore, the widespread use of cellulolytic enzymes to treat thrombolytic therapy, especially for the use of urokinase and dose also have many views. The authors advocate high-dose administration. This paper reports a large number of intravenous infusion of urokinase in retinal vein occlusion, while oral streptokinase, varicase enzyme (varidase) achieved good results. The authors treated 10 out of 10 patients diagnosed as retinal vein occlusion in outpatients within 5 months. Urokinase intravenous drip; the same time Reidase 3 times a day, each 2 pills, taken after a meal. Fibrolysis therapy drugs urokinase and streptokinase, the mechanism of action vary. Streptokinase acts on plasminogen